Halozyme Therapeutics and GSK have entered a global collaboration and license agreement to develop subcutaneous oncology therapies using Halozyme’s ENHANZE® drug delivery technology, including antibody-drug conjugates (ADCs). The deal includes upfront, milestone, and royalty payments, with GSK planning to advance multiple oncology targets under the partnership.
Written By: Chikkula Pavan Kumar, PharmD
Reviewed By: Pharmacally Editorial Team
Halozyme Therapeutics has entered a global collaboration and license agreement with GSK to develop potential subcutaneous formulations for multiple oncology therapies using Halozyme’s ENHANZE® drug delivery technology.
Under the agreement, GSK has licensed ENHANZE for the development and potential commercialization of subcutaneous versions of several oncology targets, including antibody-drug conjugates (ADCs). The collaboration also includes an option to expand the partnership to additional future drug targets.
ENHANZE is Halozyme’s proprietary drug delivery platform designed to enable rapid, large-volume subcutaneous administration of therapies that are traditionally delivered intravenously.
Halozyme stated that this marks its first collaboration focused on subcutaneous delivery of ADCs, a therapeutic class increasingly used in cancer treatment. The company noted that subcutaneous administration could potentially reduce treatment burden and improve convenience for patients compared with intravenous infusion. This deal builds on Halozyme’s growing ENHANZE portfolio, which has supported over 20 approved products across oncology and other areas.
As part of the agreement, GSK will provide Halozyme with an upfront payment along with potential future milestone payments tied to development and commercialization activities. Halozyme will also receive royalties on net sales of products incorporating ENHANZE technology. Financial terms were not disclosed.
Dr. Helen Torley, President and Chief Executive Officer of Halozyme, said the collaboration expands the company’s presence in oncology and reflects continued industry adoption of ENHANZE for subcutaneous drug delivery. She added that applying the platform to ADCs could broaden Halozyme’s commercial opportunities within a rapidly growing therapeutic area.
Eric Richards, SVP and Head of Medicine Development Leaders Oncology at GSK, said the company sees potential for subcutaneous formulations to reduce treatment burden for cancer patients and improve access to more convenient treatment options. He noted that GSK plans to advance the first clinical program under the collaboration.
Reference
About the Writer
Chikkula Pavan Kumar, PharmD is a Doctor of Pharmacy with a keen interest in clinical pharmacy, pharmacovigilance, and evidence-based practice. In his words, he is passionate about patient safety and translating complex medical information into clear, research-driven communication.